Form 4: UTHR COO Benkowitz Reports RSU Vesting, Share Transactions

United Therapeutics Corp's President and COO, Michael Benkowitz, reported the vesting of restricted stock units and related share transactions, including tax withholdings and an Employee Stock Purchase Plan acquisition.

Summary

• Michael Benkowitz, President and COO of United Therapeutics Corp (UTHR), reported changes in his beneficial ownership.
• On March 15, 2026, 17,790 and 15,592 restricted stock units (RSUs) vested, converting into common stock.
• These RSUs were originally granted on March 15, 2023.
• A total of 14,706 shares (7,837 + 6,869) were withheld by United Therapeutics for tax purposes at a price of $536.12 per share.
• An additional 62 shares of common stock were acquired on March 4, 2026, under the United Therapeutics Employee Stock Purchase Plan.
• Following these transactions, Benkowitz beneficially owns 19,046 shares indirectly through a trust and 2,710 shares directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as slightly positive, reflecting the successful vesting of executive equity compensation and a minor employee stock purchase, which are routine but demonstrate continued executive alignment with shareholder interests.

Positives

• Vesting of 33,382 restricted stock units (17,790 + 15,592) indicates successful achievement of performance criteria.
• Acquisition of 62 shares through the Employee Stock Purchase Plan demonstrates continued investment in the company.

Negatives

• Disposal of 14,706 shares for tax withholding purposes reduces direct beneficial ownership.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that routine insider filings like Form 4, detailing RSU vesting and tax-related sales, are common across the pharmaceutical and biotechnology sectors. These transactions reflect standard compensation practices and do not typically indicate a shift in company strategy or performance, but rather the execution of pre-established equity plans for executives.

Comparison to Industry Standards

• This type of RSU vesting and tax withholding transaction is standard practice for executive compensation in publicly traded companies, particularly within the biotech and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Pfizer frequently report similar Form 4 filings for their executives, reflecting the vesting schedules of their long-term incentive plans.
• The share price of $536.12 for tax withholding is specific to UTHR's valuation at the time of the transaction and is not directly comparable to other companies' share prices without context of their respective market capitalizations and stock performance.

Related Party Transactions

• Transactions involve Michael Benkowitz, President and COO, and United Therapeutics Corporation, his employer.
• Securities are held in a trust beneficially owned by the Reporting Person and his spouse, who are co-trustees.

Stakeholder Impact

• Shareholders: The vesting of RSUs and ESPP acquisition align executive interests with shareholder value, while tax-related sales are a common part of executive compensation.
• Employees: The Employee Stock Purchase Plan (ESPP) indicates a benefit available to employees, fostering broader employee ownership.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, specifically the vesting of restricted stock units and subsequent tax withholdings, along with a small employee stock purchase. Such filings are standard and do not typically provide new information that would warrant a change in investment recommendation. The transactions reflect the execution of pre-existing compensation plans rather than a strategic move or a signal about the company's future performance. Therefore, a 'hold' recommendation is appropriate as this filing does not present new fundamental data to alter an existing investment thesis.

Keywords

United Therapeutics, UTHR, Michael Benkowitz, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Employee Stock Purchase Plan, ESPP, Beneficial Ownership, Corporate Governance